CHUN-MING HONGLin, You-YuYou-YuLinCHUN-JEN LIULai, Ya-YunYa-YunLaiShiou-Hwei YehHUNG-CHIH YANGJIA-HORNG KAOSHIH-JER HSUHuang, Yi-HsiangYi-HsiangHuangYang, Sheng-ShunSheng-ShunYangKuo, Hsing-TaoHsing-TaoKuoCheng, Pin-NanPin-NanChengYu, Ming-LungMing-LungYuPEI-JER CHEN2022-09-282022-09-282021-111999-4915https://scholars.lib.ntu.edu.tw/handle/123456789/623059About 4% of the population in Taiwan are seropositive for anti-HCV Ab and 70% with HCV RNA. To address this high chronic hepatitis C disease load, Taiwan National Health Insurance started reimbursing genotype-specific DAAs in 2017 and pangenotype DAAs in mid-2018. With a 97% SVR12 rate, there were still 2-3% of patients that failed to clear HCV. To understand the causes of DAA failure in Taiwan, we conducted a multi-center, clinical, and virologic study. A total of 147 DAA-failure patients were recruited, and we searched HCV NS3/4A, NS5A and NS5B for known resistance-associated substitutions (RASs) by population sequencing, and conducted whole genome sequencing (WGS) for those without known RASs. A total of 107 patients received genotype-specific DAAs while 40 had pangenotype DAAs. Clinically, the important cause of failure is poor adherence. Virologically, common RASs in genotype-specific DAAs were NS5A-L31, NS5A-Y93, and NS5B-C316, while common RASs in pangenotype DAAs were NS5A-L31, NS5A-A/Q/R30, and NS5A-Y93. Additionally, new amino acid changes were found by WGS. Finally, we identified 12 cases with inconsistent baseline and post-treatment HCV genotypes, which is suggestive of re-infection rather than treatment failure. Our study described the drug resistance profile for DAA failure in Taiwan, showing differences from other countries.enTaiwan; chronic hepatitis C; direct-acting antiviral agent; resistance-associated substitution; treatment failure; whole genome sequencingjournal article10.3390/v13112294348351002-s2.0-85119931653WOS:000792953300028https://scholars.lib.ntu.edu.tw/handle/123456789/592981